Trial Profile
A Randomized, Open-Label, Single-Dose, 2-Way Crossover Study to Investigate the Bioequivalence of Lacosamide 200mg Administered as Intravenous Solution and Oral Tablet in Healthy Chinese Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Aug 2017
Price :
$35
*
At a glance
- Drugs Lacosamide (Primary) ; Lacosamide (Primary)
- Indications Generalised seizures; Pain; Partial epilepsies; Tonic-clonic epilepsy
- Focus Pharmacokinetics
- Sponsors UCB Biopharma
- 01 Aug 2017 Status changed from recruiting to completed.
- 04 Jul 2017 New trial record